{"id":"W4365503784","doi":"10.1200/jco.22.02152","title":"Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Genentech; PharmaMar; Eisai; Fujirebio US; Puma Biotechnology; Incyte; Clovis Oncology; Karyopharm Therapeutics; Gilead Sciences; GlaxoSmithKline; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Lenvatinib; Clinical endpoint; Internal medicine; Endometrial cancer; Oncology; Phases of clinical research; Randomized controlled trial; Clinical trial; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013613,0.0007130339,0.001814036,0.0006641704,0.0003858408,0.001200123,0.0008051045,0.001015871,0.002817426],"category_scores_gemma":[0.00579954,0.0004159691,0.002030962,0.0009598091,0.0004790483,0.001069714,0.0004976284,0.002150643,0.0005397095],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009512845,"about_ca_system_score_gemma":0.001804034,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001061508,"about_ca_topic_score_gemma":0.003670198,"domain_scores_codex":[0.9950872,0.003380866,0.0004290775,0.0002353113,0.0006262145,0.0002413459],"domain_scores_gemma":[0.9960133,0.001350274,0.001406006,0.00036256,0.0003878583,0.0004799593],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7410566,0.009971177,0.008818633,0.002843183,0.005822105,0.0001597147,0.0001848683,0.002206619,0.01850539,0.0005605191,0.009164184,0.200707],"study_design_scores_gemma":[0.6296825,0.2638009,0.06178851,0.0007194399,0.01087574,0.0007415941,0.0001420132,0.001902772,0.006058193,0.0007425275,0.02341028,0.0001355046],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9322518,0.03221004,0.003322714,0.002167189,0.0004867216,0.007833214,0.01170536,0.0002718574,0.009751068],"genre_scores_gemma":[0.9561267,0.01167759,0.00715389,0.003117709,0.0006006444,0.0038536,0.01473743,0.00009872876,0.002633687],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.013613,"threshold_uncertainty_score":0.07199329,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1125811469560184,"score_gpt":0.4825073820538253,"score_spread":0.369926235097807,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}